Gene
CYP17A1
CYP17A1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (12), Actionable biomarkers (2), Trial mentions (131), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CYP17A1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 3 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 5 of 8,738 | 0.06% | not measured | |
| 2025 | 4 of 8,875 | 0.05% | not measured | |
| 2024 | 7 of 8,597 | 0.08% | not measured | |
| 2023 | 9 of 8,275 | 0.11% | 10 of 11,460 | 0.09% |
| 2022 | 6 of 8,285 | 0.07% | 14 of 13,598 | 0.10% |
| 2021 | 13 of 8,692 | 0.15% | 17 of 15,045 | 0.11% |
| 2020 | 10 of 7,640 | 0.13% | 16 of 14,459 | 0.11% |
| 2019 | 7 of 7,300 | 0.10% | 17 of 12,159 | 0.14% |
| 2018 | 7 of 6,927 | 0.10% | 9 of 11,854 | 0.08% |
| 2017 | 9 of 6,558 | 0.14% | 13 of 11,595 | 0.11% |
Showing 10 of 37 years.
Assay-provider ledger (12)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| ABCAM | Reagent supplier | Analytical validation | 1 | November 21, 2017 |
| Affymetrix | Reagent supplier | Analytical validation | 1 | November 21, 2017 |
| Ansh Laboratories | Unclassified | Analytical validation | 1 | November 21, 2017 |
| AB Applied Biosystems | Reagent supplier | Analytical validation | 1 | November 21, 2017 |
| Chemicon | Reagent supplier | Analytical validation | 1 | November 21, 2017 |
Showing 5 of 12 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CYP17A1 expression | Enzalutamide | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
| CYP17A1 expression | Abiraterone | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (131)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02053311 | Trial eligibility (AACT) |
| NCT07260435 | Trial eligibility (AACT) |
| NCT05983783 | Trial eligibility (AACT) |
| NCT06099769 | Trial eligibility (AACT) |
| NCT01615120 | Trial eligibility (AACT) |
Showing 5 of 131 trial mentions.
Target-disease associations (259)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 17,20-lyase deficiency, isolated | endocrine system disease | Variant curation (ClinVar / EVA) |
| 17,20-lyase deficiency, isolated | endocrine system disease | genomics england |
| 17-alpha-hydroxylase/17,20-lyase deficiency, combined complete | endocrine system disease | Variant curation (ClinVar / EVA) |
| 17-alpha-hydroxylase/17,20-lyase deficiency, combined partial | endocrine system disease | Variant curation (ClinVar / EVA) |
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
Showing 5 of 259 associations.
Vendor sourcing (436)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.001%). Predicted Consequence/Location: Missense... | View ClinVar record SCV005904222.1 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Histological or cytological documentation of diagnosis of prostate cancer. * Documented progressive metastatic castrate resistant prostate cancer (mCRPC... | View trial NCT03751436 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | CYP17 | View trial NCT03751436 |
| Advanced Accelerator Applications (Italy) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Male patients, 18 years of age or older * Signed and dated written ICF by the patient or legally acceptable representative prior to any study-specific p... | View trial NCT03490838 |
| Advanced Accelerator Applications (Italy) | Trial sponsor | Mentioned in trial textTrial free-text mention | CYP17 | View trial NCT03490838 |
Showing 5 of 436 sourcing records.
Trial-cited literature (217)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01). | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2025 | 1 |
| First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. | Nature medicine | 2024 | 130 |
| The profile of steroid hormones in human fetal and adult ovaries. | Reproductive biology and endocrinology : RB&E | 2024 | 20 |
| [<sup>11</sup>C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial. | Nature medicine | 2023 | 114 |
| Polycystic Ovary Syndrome and Oxidative Stress-From Bench to Bedside. | International journal of molecular sciences | 2023 | 99 |
Showing 5 of 217 papers.
Protein variant mentions (14)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.F224S | 1 | 2015 | PMID 25741868 |
| p.I75M | 1 | 2015 | PMID 25741868 |
| p.M1V | 1 | 2015 | PMID 25741868 |
| p.P414L | 1 | 2015 | PMID 25741868 |
| p.R347H | 1 | 2015 | PMID 25741868 |
Showing 5 of 14 variants.
Literature-extracted relations (57)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Dehydroepiandrosterone | Chemical | associate |
The profile of steroid hormones in human fetal and adult ovaries. | 2024 |
| Steroids | Chemical | associate |
The profile of steroid hormones in human fetal and adult ovaries. | 2024 |
| Ketoconazole | Chemical | negative_correlate |
Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03. | 2023 |
| Lopinavir | Chemical | negative_correlate |
Lopinavir-Ritonavir Impairs Adrenal Function in Infants. | 2020 |
| Pregnenolone | Chemical | associate |
Adrenal adaptation in potassium-depleted men: role of progesterone? | 2020 |
Showing 5 of 57 relation assertions.
Organizations publishing (250)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 9 | 2014 to 2022 |
| The University of Texas System | Academic | 9 | 2011 to 2020 |
| University of Washington | Academic | 7 | 2014 to 2021 |
| Memorial Sloan Kettering Cancer Center | Hospital | 6 | 2009 to 2022 |
| University of Bern | Academic | 6 | 2012 to 2020 |
Showing 5 of 250 organizations.
Where CYP17A1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
235 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.